Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
466 Leser
Artikel bewerten:
(2)

Web Presence: Attorney Charles X Gormally on What New Jersey's Medical Cannabis Expansion Means for the State

The Garden State Rolls Out Medical Cannabis Expansion: Charles X Gormally Weighs In

MOUNTAIN LAKES, NJ / ACCESSWIRE / October 9, 2019 / This year, New Jersey's Senate, Assembly and governor signed a bill that expands access to medical cannabis in the state. However, recreational use of cannabis is still illegal at this time, though attorney Charles X Gormally said he believes legalizing recreational marijuana is the next step for New Jersey.

Charles X Gormally, a New Jersey attorney and co-chair of the Brach Eichler cannabis group, has been closely following cannabis legislation in the state. His law practice, Brach Eichler, has a cannabis group with numerous attorneys who assist in cannabis-related legal matters.

At this time, New Jersey has approximately 50,000 patients who have prescriptions for medical marijuana, but state had a limit on cannabis providers, leading to lengthy lines and supply shortages for thousands of people with a prescription for medical cannabis, according to Charles X Gormally. These people have conditions such as anxiety, cancer, multiple sclerosis, AIDS, PTSD and terminal illnesses. With the bill that was recently passed in the state, as many as 28 cannabis providers are permitted in the state.

A Cannabis Regulatory Commission has been created in the state to oversee and regulate the medical cannabis industry. Additionally, the bill that was passed, A20, will end the 6.625% sales tax on medical marijuana by the year 2022. The medical cannabis registry has recently been updated, with an option to sign up using a mobile device and with a portal for use by physicians, patients and caretakers.

The New Jersey Department of Public Health is also proposing to repeal the regulation that establishes a 10% THC limit for medical cannabis products, Charles X Gormally said. These and other new rules and regulations are in motion for the state, and he said he is excited to see it becoming more progressive. "Legalizing and expanding cannabis programs is an excellent source of income for New Jersey and would benefit the state economically in a big way," Charles X Gormally said.

Charles X Gormally lauded another element of A20, which sets a goal of giving 15% of licenses to minority owners and another 15% to women, veterans and disabled people. This shows the importance of diversity and inclusion in a bill that is already progressive, Charles X Gormally said.

The cannabis practice at Brach Eichler has eight lawyers on the team who have experience in health law, real estate, land use, corporate transactions, labor and employment and more. They are poised and ready to usher in these and future changes to cannabis legalization in New Jersey, said Charles X Gormally. For more information on the cannabis law group and cannabis law, including an educational and informative video series, visit bracheichler.com.

CONTACT:
Caroline Hunter
Web Presence, LLC
+1 7862338220

SOURCE: Web Presence, LLC



View source version on accesswire.com:
https://www.accesswire.com/562595/Attorney-Charles-X-Gormally-on-What-New-Jerseys-Medical-Cannabis-Expansion-Means-for-the-State

© 2019 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.